Pancreatic cancer has long been known as the "king of cancers" due to its poor prognosis. However, a recent study showed that adding Mitazalimab to a modified FOLFIRINOX regimen resulted in control of over 90% of patients with metastatic pancreatic cancer, with 52% of patients experiencing significant tumour shrinkage!
Search results for
"NDA"
-
-
Apparatus
Fda Accepts Zuranolone's Nda Application And Grants It Priority Review For The Treatment Of Mdd And Pdd
Approval for new FIC depression drug on the horizon!
-
Apparatus
Significantly Longer Survival In Refractory Breast Cancer With The Addition Of Eganelisib To Standard Treatment!
Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.